Purpose: The purpose of this study is to use expected value decision analysis to determine the optimal treatment for first time patellar dislocations.
Methods: A meta-analysis according to PRISMA guidelines and expected-value decision analysis were performed. A decision tree addressing the clinical question (operative vs. non-operative) was created, and a meta-analysis was performed to assess the probability of outcomes after operative versus non operative treatment. 70 patients were assessed regarding potential outcome preferences to a hypothetical injury. An expected-value decision analysis was performed to systematically quantify the clinical decision. Statistical fold back analysis calculated optimal treatment, and a sensitivity analysis was performed to determine the effect of changing redislocation rates on the expected value.
Results: Forty-five participants (mean age 20 years [range 12-33], 58% male, 71% athletes) met inclusion criteria. Meta-analysis of 10 randomized controlled trials with 624 patients revealed the probability of a "well" outcome was significantly greater for operative treatment (59.3%, 95% CI 53.7% - 64.7%) than nonoperative treatment (44.7%, 95% CI 39.0% - 50.5%). Subsequent redislocation rates with operative treatment were significantly lower (29.8%, 95% CI 24.5% - 35.17%) compared to nonoperative treatment (44.7%, 95% CI 39.0% - 50.5%). MPFL reconstruction showed an 88% probability of a "well" outcome, and a 3% redislocation rate. Operative management had a higher chance of a well outcome (RR: 1.43 (95% CI: 1.12, 1.83), p = 0.005). The overall expected value for operative treatment was 6.09 versus 4.96 for nonoperative treatment. Secondary analysis of 27 articles for solely MPFL reconstruction demonstrated an expected value of 7.80 for operative treatment.
Conclusions: Meta-analysis demonstrated more frequent favorable outcomes and lower subsequent dislocation rates with operative treatment. Decision analysis based on healthy patient responses to hypothetical scenarios demonstrates that operative treatment has a higher expected value for first time patellar dislocations than non-operative treatment.
Level Of Evidence: Level IV, economic study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arthro.2025.02.013 | DOI Listing |
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFThorac Cancer
March 2025
Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, P. R. China.
Background: Robot-assisted thoracoscopic surgery (RATS) is more precise and flexible than video-assisted thoracoscopic surgery (VATS) for early-stage non-small cell lung cancer (NSCLC) treatment. This study compared the early postoperative functional recovery of patients who underwent triportal RATS with that of patients who underwent uniportal video-assisted thoracic surgery (UVATS) for segmentectomy.
Methods: This observational, prospective study included 172 patients with clinical stage I or II peripheral NSCLC who underwent RATS or UVATS segmentectomy.
ChemMedChem
March 2025
University of Windsor, Chemistry and Biochemistry, 401 Sunset Ave., N9B 3P4, Windsor, CANADA.
Boron Neutron Capture Therapy (BNCT) leverages the nuclear reaction between boron-10 and thermal neutrons to selectively destroy cancer cells while minimizing damage to surrounding healthy tissues. This therapy has found use in treating glioblastoma, which as a brain cancer, is difficult to treat using conventional radiotherapy, surgery, and chemotherapy due to location and the risk of brain damage. However, to work, the cells must contain 10B.
View Article and Find Full Text PDFObesity (Silver Spring)
March 2025
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Objective: The objective of this study was to estimate the 10-year clinical benefits and economic value of weight loss in a Swedish population with obesity using a value of weight-loss simulation model.
Methods: Data on the prevalence of and costs associated with obesity and obesity-related complications (ORCs) were applied within an adapted simulation model to evaluate weight-loss benefits for a 2023 Swedish population over 10 years. The 10-year incidence of 10 ORCs and treatment costs in a random cohort of 10,000 individuals were estimated for a stable weight scenario and four weight-loss (5%-20%) scenarios.
Ann Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!